Finkelstein Thompson LLP Announces Investigation of BioForm Medical, Inc.
05 Janvier 2010 - 4:03PM
Business Wire
Finkelstein Thompson LLP is investigating potential claims on
behalf of shareholders of BioForm Medical, Inc. (“BioForm” or the
“Company”) (Nasdaq: BFRM) arising from the Company’s announcement
of its intent to be acquired by Merz Pharma Group (“Merz”).
On January 4, 2010, BioForm announced its plan to merge with
Merz. Under the terms of the merger agreement, BioForm shareholders
will receive $5.45 in cash for every share of BioForm stock they
own in a transaction valued at $253 million.
The investigation is focused on the potential unfairness of the
consideration to be paid to BioForm shareholders as well as the
potential unfairness of the process by which the BioForm Board of
Directors is addressing the transaction.
If you are interested in discussing your rights as a BioForm
shareholder, or have information relating to this investigation,
please contact Finkelstein Thompson's Washington, DC offices at
(877) 337-1050 or by email at contact@finkelsteinthompson.com.
Finkelstein Thompson LLP has spent over three decades delivering
outstanding representation to institutional and individual clients
in financial litigation, and has been appointed as lead or co-lead
counsel in dozens of shareholder class actions. Indeed, the firm
has served in leadership roles in cases that have recovered over $1
billion for investors and consumers.
To learn more about Finkelstein Thompson LLP, please visit our
web site at www.finkelsteinthompson.com. Attorney advertising.
Prior results do not guarantee similar outcomes.
Bioform Medical (MM) (NASDAQ:BFRM)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Bioform Medical (MM) (NASDAQ:BFRM)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Bioform Medical (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Finkelstein Thompson LLP